Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.

Rimel BJ, Pujade-Lauraine E, Moore K, Pfisterer J, Han S, Cibula D, Reyners A, Redondo A, Papadimitriou C, Eitan R, Pignata S, Glasspool R, Mirza MR, Bodnar L, Duska L, Provencher D, Phaëton R, Bains M, Coskuncay E, Hardy-Bessard AC.

Open source

DOI: 10.1093/oncolo/oyaf270
Published: 2025-10-01
Container: Oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyaf270,
  title = {Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.},
  author = {Rimel BJ and  Pujade-Lauraine E and  Moore K and  Pfisterer J and  Han S and  Cibula D and  Reyners A and  Redondo A and  Papadimitriou C and  Eitan R and  Pignata S and  Glasspool R and  Mirza MR and  Bodnar L and  Duska L and  Provencher D and  Phaëton R and  Bains M and  Coskuncay E and  Hardy-Bessard AC.},
  year = {2025},
  journal = {Oncologist},
  doi = {10.1093/oncolo/oyaf270},
  url = {https://doi.org/10.1093/oncolo/oyaf270}
}

RIS

TY  - JOUR
TI  - Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.
AU  - Rimel BJ
AU  -  Pujade-Lauraine E
AU  -  Moore K
AU  -  Pfisterer J
AU  -  Han S
AU  -  Cibula D
AU  -  Reyners A
AU  -  Redondo A
AU  -  Papadimitriou C
AU  -  Eitan R
AU  -  Pignata S
AU  -  Glasspool R
AU  -  Mirza MR
AU  -  Bodnar L
AU  -  Duska L
AU  -  Provencher D
AU  -  Phaëton R
AU  -  Bains M
AU  -  Coskuncay E
AU  -  Hardy-Bessard AC.
PY  - 2025
JO  - Oncologist
DO  - 10.1093/oncolo/oyaf270
UR  - https://doi.org/10.1093/oncolo/oyaf270
ER  -

APA

BJ, R., E, P., K, M., J, P., S, H., D, C., A, R., A, R., C, P., R, E., S, P., R, G., MR, M., L, B., L, D., D, P., R, P., M, B., E, C., & AC., H. (2025). Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.. Oncologist. https://doi.org/10.1093/oncolo/oyaf270

Source records

europe-pmc · retrieved 2026-09-26T05:38:10.415Z